Drug Trial Radar · NCT00262600
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
Last checked: Nov 20, 2026Latest source record: Apr 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18,113
Actual
Start
Dec 2005
Primary completion
Apr 2009
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- Collaborators
- Population Health Research Institute; Uppsala University
- First posted
- Dec 7, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.
Conditions
- Atrial Fibrillation
- Stroke
Interventions
warfarinDrug
once a day
Dabigatran dose 1Drug
twice daily
Dabigatran dose 2Drug
twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Yearly Event Rate for Composite Endpoint of Stroke/SEETime frame: 36 months
Locations
984 sites in 44 countries. Site status is shown where the registry gives one.
1160.26.0009 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1160.26.0046 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1160.26.0057 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1160.26.0211 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1160.26.0206 Boehringer Ingelheim Investigational Site
Huntsville, Alabama
1160.26.0115 Boehringer Ingelheim Investigational Site
Mobile, Alabama
1160.26.0104 Boehringer Ingelheim Investigational Site
Lake Havasu City, Arizona
1160.26.0304 Boehringer Ingelheim Investigational Site
Peoria, Arizona
1160.26.0185 Boehringer Ingelheim Investigational Site
Tucson, Arizona
1160.26.0305 Boehringer Ingelheim Investigational Site
Tucson, Arizona
1160.26.0038 Boehringer Ingelheim Investigational Site
Hot Springs, Arkansas
1160.26.0302 Boehringer Ingelheim Investigational Site
Jonesboro, Arkansas
1160.26.0121 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
1160.26.0191 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
1160.26.0204 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
1160.26.0213 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
1160.26.0455 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
1160.26.0388 Boehringer Ingelheim Investigational Site
Anaheim, California
1160.26.0441 Boehringer Ingelheim Investigational Site
Carmichael, California
1160.26.0145 Boehringer Ingelheim Investigational Site
French Camp, California
1160.26.0333 Boehringer Ingelheim Investigational Site
Fullerton, California
1160.26.0384 Boehringer Ingelheim Investigational Site
La Jolla, California
1160.26.0091 Boehringer Ingelheim Investigational Site
La Mesa, California
1160.26.0246 Boehringer Ingelheim Investigational Site
Lancaster, California
1160.26.0345 Boehringer Ingelheim Investigational Site
Larkspur, California
1160.26.0217 Boehringer Ingelheim Investigational Site
Loma Linda, California
1160.26.0059 Boehringer Ingelheim Investigational Site
Los Angeles, California
1160.26.0088 Boehringer Ingelheim Investigational Site
Los Angeles, California
1160.26.0337 Boehringer Ingelheim Investigational Site
Los Angeles, California
1160.26.0326 Boehringer Ingelheim Investigational Site
Mather, California
1160.26.0070 Boehringer Ingelheim Investigational Site
Merced, California
1160.26.0349 Boehringer Ingelheim Investigational Site
Oakland, California
1160.26.0016 Boehringer Ingelheim Investigational Site
Oceanside, California
1160.26.0087 Boehringer Ingelheim Investigational Site
Palm Springs, California
1160.26.0459 Boehringer Ingelheim Investigational Site
Pasadena, California
1160.26.0216 Boehringer Ingelheim Investigational Site
Redondo Beach, California
1160.26.0135 Boehringer Ingelheim Investigational Site
Riverside, California
1160.26.0162 Boehringer Ingelheim Investigational Site
Sacramento, California
1160.26.0300 Boehringer Ingelheim Investigational Site
Sacramento, California
1160.26.0371 Boehringer Ingelheim Investigational Site
Sacramento, California
Showing 40 of 984 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.